[1] Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology, 2008, 135: 1924-34, 1934.e1-4.
[2] Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology, 2005, 129: 512-521.
[3] 胆汁淤积性肝病诊断和治疗共识(2015). 实用肝脏病杂志, 2016, 19: 2-12.
[4] 于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南. 肝脏, 2015, 20:750-767.
[5] Kim SH, Katy Saide, Iohn Farrell, et al. Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury. Hepatology, 2015, 62: 887-899.
[6] Jakab SS, West AB, Meighan DM, et al. Mycophenolate mofetil for drug-induced vanishing bile duct syndrome. World J Gastroenterol, 2007, 13: 6087-6089.
[7] Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis, 2009, 29: 364-372.
[8] Fontana RJ, Shakil AO, Greenson JK, et al. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci, 2005, 50: 1785-1790.
[9] DeLemos AS, Ghabril M, Rockey DC, et al. Amoxicillin-Clavulanate-Induced Liver Injury. Dig Dis Sci, 2016, 61: 2406-2416.
[10] Foureau DM, Walling TL, Maddukuri V, et al. Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clin Exp Immunol, 2015, 180: 40-51.
[11] 熊晓梅, 李玲, 王斌. 药物性肝损伤的基因多态性研究进展.中国医院药学杂志, 2020, 40:827-830.
[12] Kaliyaperumal K,Grove JI,Delahay RM,et al.Pharmacogenomics of drug-induced liver injury (DILI): molecular biology to clinical applications. J Hepatol, 2018, 69: 948-957.
[13] Stephens C, Lopez-Nevot M, Ruiz-Cabello Francisco, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One, 2013, 8: e68111. |
